Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 15/20 | 1.00 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6939681 | 0.93 | NOS2 (0.87) | NOS2MAOAMAOBALDH1A1USP2 | |
| SCHEMBL6939204 | 0.89 | NOS2 (0.80) | NOS2MAOAMAOBALDH1A1USP2 | |
| SCHEMBL6942133 | 0.88 | NOS2 (0.78) | NOS2MAOAMAOBALDH1A1USP2 | |
| SCHEMBL6943121 | 0.87 | NOS2 (1.00) | NOS2MAOAMAOBALDH1A1USP2 | |
| SCHEMBL6943522 | 0.87 | NOS2 (1.00) | NOS2MAOAMAOBALDH1A1USP2 | |
| SCHEMBL6940129 | 0.85 | NOS2 (0.74) | NOS2MAOAMAOBALDH1A1USP2 | |
| SCHEMBL6942824 | 0.85 | NOS2 (0.74) | NOS2MAOAMAOBALDH1A1USP2 | |
| SCHEMBL6939964 | 0.83 | NOS2 (1.00) | NOS2MAOAMAOB | |
| SCHEMBL6942766 | 0.81 | NOS2 (0.68) | NOS2MAOAMAOBALDH1A1USP2 | |
| SCHEMBL6945384 | 0.81 | NOS2 (0.68) | NOS2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268471-B1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | SCHERING AG (DE) | 2003-10-15 | — | — | EP | claimed |
| US-6525051-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-02-25 | — | — | US | claimed |
| EP-1268471-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-02 | — | — | EP | claimed |
| US-20020010190-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-01-24 | — | — | US | claimed |
| WO-2001072744-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-10-04 | — | — | WO | claimed |
| EP-1268471-B1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | SCHERING AG (DE) | 2003-10-15 | — | — | EP | disclosed |
| US-6525051-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-02-25 | — | — | US | disclosed |
| EP-1268471-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-20020010190-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-01-24 | — | — | US | disclosed |
| WO-2001072744-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010190-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS3, NOS2 | NOS2 3/4885MAOA 14/4885MAOB 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.